Abcellera Biologics Stock Fair Value – The Benchmark Company Downgrades AbCellera Biologics to a Hold Rating

🌥️Trending News

ABCELLERA ($NASDAQ:ABCL): AbCellera Biologics Inc, a publicly traded company on the NASDAQ stock exchange, has recently received a downgrade in its rating from the Benchmark Company. AbCellera Biologics Inc is a biotechnology company that specializes in antibody research and development. The company utilizes cutting-edge technology to develop antibody-based drugs to treat a wide range of diseases, from cancer to autoimmune disorders. The company also offers collaboration services, antibody analytics, and research and development products. AbCellera Biologics Inc has made significant advances in the field of antibody drug development and its shares have seen impressive growth over the past year. This downgrade has caused some uncertainty among investors and has resulted in a decline in the company’s share price.

However, some analysts remain confident that AbCellera Biologics Inc will continue to expand its pipeline and develop effective treatments for a variety of diseases.

Price History

On Thursday, AbCellera Biologics Inc. experienced a 1.5% drop from its prior closing price when its stock opened at $4.8 and closed at $4.7. This marks a significant shift in the company’s financial outlook, and investors are now being urged to take caution before investing in the stock. With a hold rating, AbCellera Biologics could experience a slow rate of growth, and investors may not be able to recoup their initial investment should the stock take a dive. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Abcellera Biologics. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Abcellera Biologics. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Abcellera Biologics. More…

Key Ratios Snapshot

Some of the financial key ratios for Abcellera Biologics are shown below. More…

Analysis – Abcellera Biologics Stock Fair Value

At GoodWhale, we are pleased to present an analysis of ABCELLERA BIOLOGICS‘s financials. After carefully examining the company’s key financial metrics, our proprietary Valuation Line suggests that the fair value of ABCELLERA BIOLOGICS’s share is around $14.6. Interestingly, the current trading price of the stock is at $4.7, which indicates that the stock is undervalued by 67.7%. This could be a great opportunity for potential investors to consider buying shares of ABCELLERA BIOLOGICS. More…

Peers

Its mAbs target CD3, CD20, HER2, EGFR and other proteins. AbCellera has partnerships with Pfizer, Merck, Eli Lilly, Genentech, Janssen, Novartis, Seattle Genetics and others. The company was founded in 2012 and is headquartered in Vancouver, Canada. Ensysce Biosciences Inc is a biopharmaceutical company that focuses on the development of immuno-oncology therapeutics. Its products include ENS-761, ENS-784 and ENS-861. The company was founded in 2007 and is headquartered in La Jolla, CA. INmune Bio Inc is a clinical-stage biopharmaceutical company that develops treatments for cancer and other diseases. Its products include INK-128, INK-185 and INB-1008. The company was founded in 2015 and is headquartered in La Jolla, CA. Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company that develops immuno-oncology therapeutics. Its products include SON-101, SON-201 and SON-301. The company was founded in 2016 and is headquartered in New York, NY.

– Ensysce Biosciences Inc ($NASDAQ:ENSC)

Ensysce Biosciences Inc is a clinical stage biopharmaceutical company. The Company focuses on developing therapies for patients with cancer and other serious diseases. Ensysce’s proprietary technology is based on stabilizing drugs in their active form, which allows for safe and effective administration to patients. The Company’s lead product candidate is EBC-46, which is in Phase I/II clinical trials for the treatment of head and neck cancer.

– INmune Bio Inc ($NASDAQ:INMB)

Innate Immunotherapeutics is a clinical-stage biotechnology company developing medicines to treat autoimmune and inflammatory diseases. The company has a market cap of $126.88M as of 2022 and a Return on Equity of -27.44%. Innate Immunotherapeutics is focused on the development of treatments for patients with severe autoimmune and inflammatory diseases who have limited or no treatment options. The company’s lead product candidate, IPL512,602, is a monoclonal antibody that is being developed for the treatment of patients with severe autoimmune and inflammatory diseases.

– Sonnet BioTherapeutics Holdings Inc ($NASDAQ:SONN)

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of novel, small molecule therapeutics for the treatment of cancer. The company’s product pipeline includes SNT-100, SNT-101, and SNT-102. Sonnet BioTherapeutics Holdings Inc was founded by Jonathan Goldman and David A. Goldman in 2015 and is headquartered in New York, NY.

Summary

AbCellera Biologics Inc has recently been downgraded to a “Hold” from a “Buy” rating by The Benchmark Company. This is noteworthy for potential investors as the company had previously been considered a strong buy. The decision reflects a decreased confidence in the stock’s future due to current market conditions. Despite this downgrade, AbCellera Biologics Inc still remains a viable option for investors who are confident in the company’s long term prospects.

The company specializes in the development and commercialization of advanced antibody therapeutics, providing potential investors with a unique opportunity to capitalize on the growing biotechnology sector. With a focus on innovative research and development, AbCellera Biologics Inc should continue to be a leader in the industry, offering potential investors an attractive investment opportunity when considering upwards performance potential.